These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 35050803)

  • 1. Acute phase reactant proteins in Buerger's disease: Is it a systemic disease?
    Keramat S; Karahan O; Patel M; Fazeli B
    Vascular; 2023 Jun; 31(3):473-476. PubMed ID: 35050803
    [No Abstract]   [Full Text] [Related]  

  • 2. Thromboangiitis obliterans episode: autoimmune flare-up or reinfection?
    Mohareri M; Mirhosseini A; Mehraban S; Fazeli B
    Vasc Health Risk Manag; 2018; 14():247-251. PubMed ID: 30319267
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcomes of Anticoagulant Therapy with Low-Molecular-Weight Heparin (LMWH) and Warfarin for Thromboangiitis Obliterans (TAO).
    Gao J; Huang L; Wang J
    Curr Vasc Pharmacol; 2021; 19(6):655-662. PubMed ID: 33461467
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Decrease in prevalence of Buerger's disease in Japan.
    Matsushita M; Nishikimi N; Sakurai T; Nimura Y
    Surgery; 1998 Sep; 124(3):498-502. PubMed ID: 9736901
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The IL-33/sST2 Axis in Thromboangiitis Obliterans.
    Sharebiani H; Mohareri M; Mirhosseini A; Fazeli B
    J Inflamm Res; 2020; 13():317-323. PubMed ID: 32765040
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stem cell therapy for treatment of thromboangiitis obliterans (Buerger's disease).
    Cacione DG; do Carmo Novaes F; Moreno DH
    Cochrane Database Syst Rev; 2018 Oct; 10(10):CD012794. PubMed ID: 30378681
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Endovascular Treatment of Thromboangiitis Obliterans (Buerger's Disease).
    Modaghegh MS; Hafezi S
    Vasc Endovascular Surg; 2018 Feb; 52(2):124-130. PubMed ID: 29237360
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacological treatment for Buerger's disease.
    Cacione DG; Macedo CR; do Carmo Novaes F; Baptista-Silva JC
    Cochrane Database Syst Rev; 2020 May; 5(5):CD011033. PubMed ID: 32364620
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Decrease in the incidence of Buerger's disease recurrence in northern Thailand.
    Laohapensang K; Rerkasem K; Kattipattanapong V
    Surg Today; 2005; 35(12):1060-5. PubMed ID: 16341487
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An Iranian scoring system for diagnosing Buerger's disease.
    Ramin M; Salimi J; Meysamie A
    Acta Med Iran; 2014 Feb; 52(1):60-5. PubMed ID: 24658990
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological treatment for Buerger's disease.
    Cacione DG; Baptista-Silva JC; Macedo CR
    Cochrane Database Syst Rev; 2016 Feb; 2():CD011033. PubMed ID: 26828199
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Buerger's disease and anticardiolipin antibodies.
    Pereira de Godoy JM; Braile DM
    J Cardiovasc Med (Hagerstown); 2009 Oct; 10(10):792-4. PubMed ID: 19455050
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of omental transfer in Buerger's disease: New Delhi's experience.
    Singh I; Ramteke VK
    Aust N Z J Surg; 1996 Jun; 66(6):372-6. PubMed ID: 8678856
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of thromboangiitis obliterans (Buerger's disease) by intramuscular gene transfer of vascular endothelial growth factor: preliminary clinical results.
    Isner JM; Baumgartner I; Rauh G; Schainfeld R; Blair R; Manor O; Razvi S; Symes JF
    J Vasc Surg; 1998 Dec; 28(6):964-73; discussion 73-5. PubMed ID: 9845647
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Efficacy of Percutaneous Transluminal Angioplasty on the Limb Salvage and Recovery of Symptoms in Patients With Buerger's Disease With Critical Limb Ischemia.
    Rodoplu O; Yildiz CE; Oztas DM; Conkbayir C; Unal O; Ulukan MO; Meric M; Ugurlucan M; Kirbas A
    J Invasive Cardiol; 2020 Jun; 32(6):E158-E167. PubMed ID: 32479418
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Humoral and cellular immune response to Buerger's disease.
    Ehteshamfar SM; Afshari JT; Modaghegh MS; Mahmoudi M; Kazemzadeh GH; Kermani FS
    Vascular; 2020 Aug; 28(4):457-464. PubMed ID: 32212917
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endothelial dysfunction in Buerger's disease and its relation to markers of inflammation.
    Joras M; Poredos P; Fras Z
    Eur J Clin Invest; 2006 Jun; 36(6):376-82. PubMed ID: 16684120
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Buerger's disease (thromboangiitis obliterans): an analysis of the arteriograms of 119 cases.
    Suzuki S; Mine H; Umehara I; Yoshida T; Okada Y
    Clin Radiol; 1982 Mar; 33(2):235-40. PubMed ID: 7067357
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical outcomes of extended endovascular recanalization of 16 consecutive Buerger's disease patients.
    Kacmaz F; Kaya A; Keskin M; Keceoglu S; Algin IH; Yilmazkaya B; Ilkay E
    Vascular; 2019 Jun; 27(3):233-241. PubMed ID: 30305010
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Asymmetric dimethylarginine levels in Buerger's disease.
    Tuygun AK; Tuygun A; Yurtseven N; Sensöz Y; Günay R; Keser M; Tuygun UH; Ketenci B; Sahin S; Yekeler I
    Ann Vasc Surg; 2011 May; 25(4):547-54. PubMed ID: 21439775
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.